A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03255070 |
Recruitment Status :
Recruiting
First Posted : August 21, 2017
Last Update Posted : March 11, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Neoplasms Gastric Neoplasm Solid Tumors | Drug: ARX788 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 190 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | This is a 2-part, Phase 1, open-label study will administer the IMP, ARX788 by IV infusion every 3, 4 or 6 weeks. Sequential dose escalation cohorts are planned using a 3+3 design. A cohort may be expanded to collect additional data if recommended by Safety Monitoring Committee based on comprehensive reviews of safety, tolerability and PK data to determine RP2D. Phase 1a will determine the recommended Phase 2 dose (RP2D) in subjects with advanced cancer whose HER2 test results are in situ hybridization (ISH) positive or immunohistochemistry (IHC) 3+. Phase 1b will assess anticancer activity and safety in advanced cancer. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression |
Actual Study Start Date : | March 20, 2018 |
Estimated Primary Completion Date : | August 2022 |
Estimated Study Completion Date : | March 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: ARX788 Phase 1a (Dose Escalation)
ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.
|
Drug: ARX788
An antibody drug conjugate
Other Name: antibody drug conjugate (ADC) |
Experimental: ARX788 Phase 1b (Dose Expansion)
ARX788 will be administered every 3 weeks (Q3W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
|
Drug: ARX788
An antibody drug conjugate
Other Name: antibody drug conjugate (ADC) |
- Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs) [ Time Frame: Day 1 through 30 days after last dose ]To assess the safety, tolerability, and immunogenicity profile
- Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1. [ Time Frame: 36 months ]Number of subjects with objective response is assessed every 6-8 weeks from Cycle 1 Day 1 through disease progression.
- Number of subjects with tumor response per imaging assessment based on RECIST version 1.1. [ Time Frame: 18 months ]The objective response rate (ORR: CR+PR) based on RECIST v1.1 will be assessed as the primary endpoint to determine the anticancer activity of ARX788 as well as best overall response.
- Area under the concentration-time curve (AUC) from first infusion to subject end of study. [ Time Frame: 36 months ]Pharmacokinetic (PK) characteristics: ARX788 (intact ADC), total mAb, and metabolites
- Half-life of ARX788 from first infusion to end of study. [ Time Frame: 36 months ]Pharmacokinetic (PK) characteristics: ARX788 from first infusion to subject end of study
- Immunogenicity profile of ARX788 [ Time Frame: 36 months ]Number of subjects who develop anti-ARX788 antibody

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >18 years
- Life expectancy >3 months.
- Female or male subjects whose advanced HER2 expressing cancer has failed standard of care treatments, or for whom such therapy is not acceptable to the subject. Subjects with advanced breast, gastric cancer, or other solid tumor who test positive for HER2 by ASCO/CAP criteria (either IHC or FISH) must have received prior treatment with a trastuzumab containing therapy. Subjects who have been previously treated with pertuzumab, TDM-1, lapatinib, or other available and accessible HER2-directed therapies or investigational therapies are eligible.
-
Disease measurability:
- Phase 1a: measurable or non-measurable disease per RECIST v 1.1.
- Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b).
- Histopathologic evidence of cancer based upon pathology report.
-
Tumor tissue local laboratory HER2 testing results, adequate tumor sample available for confirmation of HER2 status. Subjects with other types of cancer must have previously tested locally for HER2 status by HER2 IHC or ISH assay.
- Phase 1a: ISH positive or IHC 3+ advanced cancer (including breast or gastric/esophageal or other solid tumors).
- Phase 1b: Cohort 8 advanced breast cancer (IHC 3+ or IHC 2+/ISH); Cohort 9 advanced breast cancer (IHC 2+ / ISH-); Cohort 10 advanced gastric cancer (IHC 3+ or IHC 2+/ISH+) or gastroesophageal junction adenocarcinoma; Cohort 11 other advanced solid tumor cancers with HER2-overexpression (HER2 IHC 3+ or IHC 2+/IHS+); Cohort 12 advanced solid tumor cancers with HER2 activating mutation.
- Eastern Cooperative Oncology Group Performance Status of 0 to 1.
- Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the NCI-CTCAE v 4.03 (phase 1a) and v 5.0 ( Phase 1b).
- Adequate organ functions.
- Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol.
- Female subjects must be surgically sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or who commits to use an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 3 months following the last dose of study treatment.
- Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study.
Exclusion Criteria:
- History of allergic reactions to any component of ARX788.
- History of ocular events, or any current ongoing active ocular infections.
- History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia within 12 months prior to enrollment
- Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0)
- History of unstable central nervous system (CNS) metastases
- Current severe, uncontrolled systemic disease (eg, clinical significant cardiovascular, pulmonary, or metabolic diseases)
- Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments.
- Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788.
- Clinically significant surgical intervention (excluding diagnostic biopsy) within 21 days of the first dose of ARX788
- Radiotherapy administered less than 21 days prior to the first dose of ARX788, or localized palliative radiotherapy administered less than 7 days prior to the first dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on NCI-CTCAE v 5.0.
- Pregnancy or breast feeding.
- Known active HCV, HBV, and/or HIV infection.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03255070
Contact: Trial Inquiry | 858-875-2400 | pantumor01trialinquiry@ambrx.com |
United States, California | |
USC Norris Cancer Hospital | Recruiting |
Los Angeles, California, United States, 90033 | |
Contact: Janice Lu, M.D. | |
Principal Investigator: Janice Lu, M.D. | |
UCLA Hematology-Oncology | Recruiting |
Santa Monica, California, United States, 90095 | |
Contact: Sara Hurvitz, M.D. | |
Principal Investigator: Sara Hurvitz, M.D. | |
United States, Missouri | |
Washington University School of Medicine | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
Contact: Haeseong Park, M.D. | |
Principal Investigator: Haeseong Park, M.D. | |
United States, Ohio | |
Cleveland Clinic | Recruiting |
Cleveland, Ohio, United States, 44195 | |
Contact: Thomas Budd, M.D. | |
Principal Investigator: Thomas Budd, M.D. | |
United States, Texas | |
Baylor Sammons Cancer Center | Recruiting |
Dallas, Texas, United States, 75246 | |
Contact: Joyce O'Shaughnessy, M.D. | |
Principal Investigator: Joyce O'Shaughnessy, M.D. | |
Australia, New South Wales | |
Albury Wodonga University Hospital | Recruiting |
East Albury, New South Wales, Australia, 2640 | |
Contact: Richard Eek, M.D. | |
Principal Investigator: Richard Eek, M.D. | |
Australia, Queensland | |
Mater Misericordiae Limited | Recruiting |
South Brisbane, Queensland, Australia, 4101 | |
Contact: Catherine Shannon, M.D. | |
Principal Investigator: Catherine Shannon, M.D. | |
Princess Alexandria Hospital | Recruiting |
Woolloongabba, Queensland, Australia, 4102 | |
Contact: Katharine Cuff, M.D. | |
Principal Investigator: Katharine Cuff, M.D. | |
Australia, Victoria | |
Monash Health | Recruiting |
Clayton, Victoria, Australia, 3168 | |
Contact: Sophia Frentzas, M.D. | |
Principal Investigator: Sophia Frentzas, M.D. |
Study Director: | Ambrx | Ambrx, Inc. |
Responsible Party: | Ambrx, Inc. |
ClinicalTrials.gov Identifier: | NCT03255070 |
Other Study ID Numbers: |
ARX788-1711 |
First Posted: | August 21, 2017 Key Record Dates |
Last Update Posted: | March 11, 2022 |
Last Verified: | February 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
HER2 antibody drug conjugate breast cancer gastric cancer |
advanced solid tumors HER2-overexpression HER2-mutations |
Neoplasms Breast Neoplasms Stomach Neoplasms Neoplasms by Site Breast Diseases Skin Diseases Gastrointestinal Neoplasms |
Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Immunoconjugates Immunologic Factors Physiological Effects of Drugs |